Vaccination programs have had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants (e.g., Novartis’s Kesimpta, Bristol Myers Squibb’…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
Amyotrophic lateral sclerosis (ALS) is a progressively debilitating disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of…
Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States and Europe. The majority of…
The type 2 diabetes (T2D) therapy market will expand over the first half of the 2021-2031 forecast period. This increase will be partly fueled by a rich pipeline of novel agents; emerging…
The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…
Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…
Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant…
The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore…
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to various…
The rising rates of antimicrobial resistance (AMR) have created an emergent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Since the emergence of the…
Since 2015, eleven new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon…